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SUMMARY 
The massive implementation of the vaccine and antiviral agents against Hepatitis B Virus (HBV), 
targeting the envelope and viral polymerase genes, induces a selection pressure that might lead to 
the emergence of variants that impair the effectiveness of the vaccine, diagnostic methods and 
antiviral therapy. 
The aim of this study was to evaluate the prevalence of HBV vaccine escape (VEMs), diagnostic 
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HBV surface antigen and polymerase sequences obtained from serum samples of 530 HBV-
infected individuals were analyzed. 
Samples belonged to genotype A (28.1%), D (13.6%) and F (58.3%). VEMs, DMFs and ARMs were 
present in 40 (7.5%), 57 (10.7%) and 27 (5.1%) samples within the studied population. Additionally, 
eight non-previously reported VEMs and nine DFMs were identified. VEMs and DFMs were biased by 
genotype, being higher in genotype D (33.3% and 33.3%) compared to genotype A (6% and 17.4%) 
and genotype F (2.3% and 2.3%), (p>0.001). On the contrary, there was no association between the 
presence of ARMs and HBV genotype (p=0.324). 
VEMs, DFMs and ARMs create public health concerns. The current study provided valuable 
information about mutants in surface antigen and polymerase in HBV-infected patients from 
Argentina where HBV-F is the most prevalent genotype. Consequently, it constitutes an important 
reference for Latin American clinicians in order to optimize the management of HBV infected 
patients.  
 
KEYWORDS: Hepatitis B Virus; Vaccine Escape Mutant, Antiviral Resistance, Diagnostic Failure. 
 
Introduction 
Hepatitis B virus (HBV) infection and HBV-related complications remain a major global public health 
problem1 since an estimated 260 million people are chronically infected2 and more than 800.000 
deaths occur yearly, mostly from complications, including cirrhosis and hepatocellular carcinoma. 
HBV has a small partially double-stranded relaxed circular DNA genome, which has a very compact 
coding organization with four partially overlapping open reading frames. 
Based on genetic divergence, HBV has been classified into 9 genotypes designated A-I defined by 
>8% divergence at the nucleotide level and several subgenotypes, while another putative genotype, 
“J” have been proposed after isolation from one individual3. Genotypes and subgenotypes have a 
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Due to the absence of proofreading activity, the HBV polymerase/RT leads to the introduction of 
random mutations into HBV genome, creating a genetic variability described as viral quasispecies. 
These variants include vaccine escape mutants (VEMs), diagnostic failure mutants (DFMs) in the 
routine screening and antiviral drug-resistance mutations (ARMs)5. 
HBV vaccine was introduced in the early 1980s and currently, the global coverage with three doses is 
estimated at 82%6. In Argentina, vaccination against HBV was finally incorporated into the calendar 
for newborns since 2000. 
The current recombinant Hepatitis B surface antigen (HBsAg) used in HBV vaccine and diagnostic 
assays, contains a highly conserved antibody-neutralizing epitope cluster which spans amino acids 
(aa) 124-147 within the major hydrophilic region (MHR, aa 99-169), and is referred to as “a” 
determinant. It is known that neutralizing antibodies produced after vaccination against HBV are 
targeted to the conformational epitopes of the “a” determinant7-9. 
Despite the high efficacy of HBV vaccine, breakthrough infections due to VEMs have been reported 
in vaccinated individuals, which highlights the importance of these escape mutants. Additionally, 
these variants may also provide false negative results in serological tests, which are known as false 
occult HBV infection (OBI)7,10. 
Furthermore, in the last decades several oral nucleos(t)ide analog (NA) were approved for HBV 
chronic infection treatment. The viral target of these antiviral agents is the RT domain of the HBV 
polymerase11. Under selective pressure imposed by the administration of antiviral agents, minor HBV 
quasispecies converge on a dominant mutant that can escape selection pressure, creating a drug-
resistant HBV strain. 
As mentioned before, the HBV genome is organized in such a way that the surface antigen gene is 
completely overlapped with the polymerase one12. Therefore, polymerase gene mutations selected 
during the course of antiviral NAs therapy may affect neutralization epitopes within the HBsAg. 
Most epidemiological data of HBV surface and polymerase mutants have been based on studies 
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with a paucity of information regarding infections with other genotypes13-16. Particularly, information 
about genotype F, characteristic of Native American populations of Alaska, South and Central 
America and likely originated in Amerindian populations was scarcely addressed17-19.  
Additionally, there is no information about VEMs, DFMs and ARMs prevalence in Argentina. Thus, we 
aimed to evaluate the prevalence of HBV vaccine escape, diagnostic failure and drug-resistance 
mutants in HBV chronically infected individuals from Buenos Aires, Argentina. 
 
Materials and Methods 
Study population  
In a retrospective cross-sectional study, 530 HBsAg carriers who attended a tertiary care center 




HBV serological markers were analyzed with AxSYM, Abbott Diagnostics, USA (samples before 2010) 
and Architect Abbott system; Abbott Diagnostics, Wiesbaden, Germany (samples since 2010). 
 
HBV-DNA extraction, amplification and sequencing  
DNA was extracted from 200 µl of serum using the High Pure Viral Nucleic acid kit (Roche 
Diagnostics, Germany). The HBsAg gene was amplified with primers HBVS1 (sense, 5’ TCA CCA TAT 
TCT TGG GAA CAA GA 3’, 2821–2843) and HBVS2 (antisense, 5’ AAA ACC CAA AAG ACC CAC AAT 3’, 
1017-997) and HBVS3 (sense, 5′ CTG CTG GTG GCT CCA GTT C 3′, 57-75) and HBVS4 (antisense, 5′ 
CAA AAG AAA ATT GGT AAC AGC GG 3′, 816-794) for the second round. The first PCR round 
encompasses the entire S region and the Pol region from amino acid 178 to 637 (rtPol aa 1 to 289), 
while the second PCR round encompasses the S region from amino acid 1 to 213 and the Pol region 
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extracted DNA and 0.25 µM of each primer were added to AmpliTaq Gold® 360 Master Mix in a final 
volume of 25 µL. For the second round, 2 µL of first round product were added to 40 µL final volume 
of PCR mix. The cycling protocol was: denaturing at 94°C 5 min; followed by 40 cycles in the first 
round and 25 cycles in the second one of 94°C 30 sec, 53°C 30 sec and 72°C 1 min followed by a final 
extension at 72°C for 5 min. 
The PCR product of the first round (1416 nt) or the second round (759 nt) was purified using 
QIAquick Gel Extraction Kit (Qiagen, Valencia, CA, USA) and submitted to direct nucleotide 
sequencing reaction in both directions (Unidad de Genómica, INTA, Castelar, Buenos Aires, 
Argentina) with the same primers used in amplification stage. 
 
HBV Typing 
Genotyping was assessed by phylogenetic analysis. Seventy-one nucleotide sequences spanning 
about 759 nt from HBsAg region representing the different HBV genotypes were retrieved from 
GenBank and used as references. Sequences obtained in this study and HBV sequences from 
GenBank database were aligned with ClustalX (v2.1) software20 and edited with BioEdit (v7.1.3.0) 
software21. Phylogenetic trees were constructed using the Maximum Likelihood method performed 
with RAxML (v 8.0.24) program22. Evolutionary models were inferred according to the Akaike 
Information Criterion (AIC) statistics obtained with jModeltest (v2.1) software23. Robustness of the 
reconstructed phylogenies was evaluated by bootstrap analysis (1000 replicates). In order to 
differentiate among subgenotypes, phylogenetic analyses were combined with amino acid and 
nucleotide patterns characteristic of each subgenotype within the HBsAg; this was assessed by 
VisSPA v1.6.2 program24. It was established that the amino acid pattern characteristic of each 
subgenotype would be formed by at least 90% of the amino acids present in the sequences from the 
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Mutational Analysis 
Nucleotide sequences were aligned and occurrence of each aminoacid at each position of the 
alignment was analyzed using the Positional Aminoacid Numerical Summary tool included in Bioedit 
(v7.1.3.0) followed by visual inspection. In order to search for most significant HBV surface mutants, 
aa 99-169 within HBsAg gene were examined. Fourteen positions related with VEMs (116, 118, 120, 
126, 129, 130, 131, 133, 134, 141, 142, 143, 144 and 145) and thirty related with DFMs (100, 101, 
115, 116, 118, 120, 121, 122, 123, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 141, 142, 143, 
144, 145, 146, 147, 148, 154, 155 and 157) were analyzed in this work according to previous 
reports16-18,25-28. Additionally, eleven positions in the polymerase gene (rtL80, rtI169, rtV173, rtL180, 
rtA181, rtS184, rtA194, rtS202, rtM204, rtN236T and rtM250V) were also investigated in order to 
evaluate ARMs for the most widely used antivirals29,30. Mutations at positions rtN236 and rtM250V 
were determined in 356 out of the 530 samples. 
 
Statistical Analysis  
Frequencies were compared using the chi-square test or the Fisher’s test. The Student’s t-test and 
the Mann-Whitney U were used for comparing continuous variables. The statistical analysis was 
carried out using the SPSS statistical software package release 19.0 (IBM SPSS Inc, Chicago, IL, USA). 
  
Nucleotide Sequences Accession Numbers  
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Ethical aspects 
Written informed consents to participate in this study were obtained from the patients. The 
study protocol was approved by the ethics committee from “Facultad de Farmacia y 
Bioquímica, Universidad de Buenos Aires” (record number 02032015-2/2015) in accordance 
with the 1975 Helsinki Declaration. 
 
Results  
Characteristics of the study population  
Serum samples from 530 patients HBsAg and anti-HBc positive were analyzed. Median (Q1-Q3) age 
was 44 (36-57) years and 375 (70.7%) were male. Fourteen patients asserted having received 
antiviral treatment, 8 with Entecavir, 5 with Lamivudine, and 1 with Adefovir. Epidemiological 
characteristics of the study cohort are shown in Table 1. 
Phylogenetic analysis of HBsAg gene showed supported clusters (bootstrap >70) for each genotype 
(data not shown). The overall genotype distribution was: HBV-A 149 (28.1%), HBV-D 72 (13.6%) and 
HBV-F 309 (58.3%). In the same way, HBV subgenotypes were in the following proportions: HBV-A1 
5.7%; HBV-A2: 22.4%; HBV-D1: 3.8%; HBV-D2: 2.5%; HBV-D3: 5.8%; HBV-D4: 1.5%; HBV-F1b: 39.8%; 
and HBV-F4: 18.5%. The patients age was evenly distributed among the different genotypes: HBV-A 
45 (37-56), HBV-D 44 (36-58) and HBV-F 44 (34-57), p=0.900. 
 
Vaccine Escape Mutant Analysis 
Forty-four VEMs were detected in 40 out of 530 samples (7.5%). In this regard, single mutations 
were observed in 36 cases and double mutations in 4 cases. All VEMs were observed in 11 out of 14 
aa residues analyzed, while three positions (T116, Q129 and K141) were unchanged in all cases. 
Additionally, 4 non-reported mutations, namely G130R (2), M133I and P142T were observed. Table 2 
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The most frequent VEMs were: T118A/V (2.26%), M133L/T 1.13%), P143L (0.94%) and D144A/E/G 
(0.94%). Patients infected with HBV-D showed a higher prevalence of VEMs (33.3%) than patients 
infected with HBV-A (6%) or HBV-F (2.3%), respectively (p<0.001). Moreover, one patient infected 
with HBV-D (1.4%) and 3 infected with HBV-A (2%) presented more than one VEM (p<0.053). The 
age of the patients with VEMs was 49 (38-61) versus 44 (36-57) in those without VEMs (p=0.286).  
Since it was reported that subgenotypes other than A2 (present in the vaccine antigen) produce a 
suboptimal protection against infection, VEMs were also analyzed according to the subgenotype. In 
this sense, subgenotypes F1b, F4 and A1 presented a low frequency of VEMs (1.9%, 3.1% and 3.3%) 
respectively. Subgenotypes D1 and A2 presented an intermediate frequency of VEMs (5% and 6.7%) 
and subgenotypes D2, D3 and D4 presented very high frequencies of VEMs (100%, 25.8% and 25%) 
respectively (p <0.001). The prevalence of VEMs was significantly higher in patients with normal ALT 
than in those with elevated ALT levels [14.9% vs. 5.4% (p <0.005)] and in HBeAg-negative patients 
compared to HBeAg-positive patients [16.5% vs. 3% (p <0.001)]. 
 
Diagnostic Failure Mutant Analysis 
Seventy-two DFMs were detected in 57 out of 530 samples (10.7%). Those changes included 43 
isolates with a single mutation, 13 isolates with double mutation and 1 with a triple mutation. Forty-
one out of 72 DFMs were shared with the VEMs, given that 14 of the 30 analyzed positions overlap 
with those of the VEMs. Additionally, thirty-one DFMs were detected: Y100C (14), Q101K (3), A128V 
(10), G130R (2), M133I and N146S. The most frequent DFMs were the same previously mentioned 
for VEMs plus Y100C (2.64%) and A128V (1.88%) (Table 2). 
On the other hand, 14 positions (T115, T116, C121, KR122, Q129, T123, P135, C137, C138, K141, 
C147, T148, S155 and A157) remained unchanged in all cases. Furthermore, nine non-reported 
substitutions in six of the 30 positions, namely Y100W (3), Q101P, P120A, M133L (2), P142T and 
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As observed for VEMs, patients infected with HBV-D showed a higher prevalence of DFMs (33.3%) 
than patients infected with HBV-A (17.4%) or HBV-F (2.3%), respectively (p<0.001). Moreover, 11 
patients infected with HBV-D (15.3%) harbored two or more DFMs simultaneously, while only 3 
infected with HBV-A (2%) and none infected with HBV-F presented more than one DFMs (p<0.001). 
Additionally, it has been described that several combinations of DFMs displayed lower reactivity with 
at least one commercial diagnostic assay (Y100C/P120T, S113T/G130N, P120S/S143L, T123N/143S, 
F134V/D144G, T126S/G145R, P142L/G145R, P142S/G145R, D144A/G145R and 
P120Q/T131K/G145R). However, none of these combinations was observed in our samples. Finally, 
patient’s age and ALT levels were not associated with the frequency of DFMs [45 (38-61) in patients 
with DFMs versus 44 (36-56) in those without DFMs (p=0.235) and 11.9% vs. 9.1% in patients with 
normal or elevated ALT levels, respectively]. On the other hand, the number of DFM was associated 
with the presence of HBeAg. In this regard, the prevalence of DFM was higher in HBeAg-negative 
patients than those HBeAg-positive (15.7% vs. 7.1%, p=0.009, respectively). 
Lastly, twelve out of 28 (42.8%) mutational types observed in the HBsAg gene had different 
frequency according to genotype (Table 2). Among them, it is worth mentioning, Y100C which was 
highly prevalent in HBV-A (almost exclusive in HBV-A1, 13 out of 14 mutational types) and A128V, 
G130N, F134N and ST143L, which were mainly detected in genotype D (12.5%, 2.8%, 2.8% and 6.9%, 
respectively).  
 
Antiviral Resistant Mutations Analysis 
ARMs were detected in 27 samples (5.1%) in 6 out of 11 aa residues analyzed. The 27 mutated 
isolates included 5 isolates with a single mutation, 13 isolates with double mutations, 8 with a triple 
mutation and 1 with four mutations (Table 3). 
The most frequent ARMs were: rtL180M (3.8%) and rtM204V/I (3.8%). Mutations of rtL80 (0.8%), 
rtV173L (1.2%), rtT184 (0.8%), and rtS202 (1%) had a lower pooled incidence. Five positions (rtI169, 
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observations, prevalence of ARMs was independent from HBV genotype [HBV-A (6.7%), HBV-D 
(6.9%) and HBV-F (3.9%), p=0.324]. The prevalence of ARMs, as expected, was significantly higher in 
those patients who reported having received antiviral treatment (78.6%) than in naïve patients 
(3.1%), p<0.001. Moreover, all observed mutations were related to the received treatment. 
Finally, patient’s age and HBeAg status was not associated with the presence of ARMs. In this regard, 
age was 50 (30-64) in patients with ARMs versus 44 (36-57) in those without ARMs, (p=0.376) and 




The present work represents, to our knowledge, the first study that estimates the prevalence of 
vaccine escape mutations, diagnostic failure mutations and antiviral resistance mutations in a size 
representative cohort of HBV-infected patients from Buenos Aires, Argentina and the largest study 
analyzing these mutants in genotype F.  
 
Since the beginning of the 90s, the emergence and increment of VEMs due to vaccine 
implementation has been described18,25,31,32. HBV strains carrying VEMs represent an epidemiological 
concern since they have the potential to infect even immunized population. Frequency of VEMs in 
literature covers a wide range from less than 5% to more than 40%14,16,19,25-27,31,33. Different variables 
such as cohort size, prevalence of infection, time of introduction or mandatory implementation of 
vaccination, region analyzed and viral genotypes can affect the rate of VEMs, which hinders 
comparison of studies. 
In this study, VEMs were present in 7.5% of cases and most of them were located in the ‘‘a’’ 
determinant. This result is consistent with other studies performed in Spain (6.6%), Turkey (8.3%) 
and China (9.01%)16,25,33. The population included in this study was not reached by vaccine 
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The gradual increase of VEMs over time, as well as other shortcomings of current vaccines, has led to 
the development of vaccines that include homologous HBsAg subtypes to different regions and 
neutralizing epitopes of preS1 and preS2 of the predominant HBV strains34,35.  
There is growing evidence that HBV genotypes may play a role in causing different disease profiles in 
chronic hepatitis B infection36. Furthermore, there is evolving evidence that HBsAg variants may 
influence HBV vaccine and treatment response37,38. Several studies have addressed the association 
of HBV genotype and VEMs17,39,40. This association was observed in the cohort analyzed herein, being 
significantly higher in genotype D (33%) than in A (6%) or F (2.3%) ones. This result is in accordance 
with Ma´s study where they observed that HBV genotypes A–D tended to be more prone to harbor 
VEMs, supporting that genotypes may display different clinical implications on the S gene variability 
for virus vaccine design17.  
Additionally, in a recent study carried out in Australia, a suboptimal protection against infections 
caused by subgenotypes other than the antigen present in the vaccine (HBV-A2) was observed41. 
However, in our study, the lower frequencies of VEMs were observed in subgenotypes F1b, F4 and 
A1, while D1 and A2 showed intermediate prevalence and D2, D3 and D4 presented very high 
prevalence of VEMs. 
Interestingly, more than a half of the samples analyzed in this study (58.3%) grouped as genotype F. 
This represents a relevant fact since data about VEMs in this genotype, one of the most prevalent in 
Latin America and Alaska42-49, is very scarce. In this regard, genotype F was frequently associated 
with hepatitis infections in vaccinated individuals50,51. Despite this, in this work we have observed 
that the prevalence of VEMs for genotype F is very low. The effectiveness of HBV vaccine against 
different genotypes is a controversial issue. Although many studies have demonstrated that the 
current vaccine (HBV A2-based) provides broad protection against the different HBV genotypes6, 
other studies have postulated that protection against more divergent genotypes, such as genotype F 
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Detection of HBsAg is crucial for HBV infection diagnosis and routinely used either for testing of 
individuals with suspected HBV infection or for screening in blood donors54. 
In the present study, DFMs were observed in 10.7% of the cases, and most of the mutations 
overlapped with previously described VEMs. Nonetheless, several DFMs outside the ‘‘a’’ 
determinant were observed. Likewise VEMs, DFMs showed a biased distribution by genotype. 
Twenty-two of the 28 mutation types observed in the analyzed positions had demonstrated low 
ability to bind antibodies16-18,25-27. The most frequent mutation position was Y100C in HBV-A1 
(43.3%). This mutation was frequently detected in negative-HBsAg samples and was statistically 
associated with “false” OBI in other studies55-57. In addition, we observed many other mutations in 
the MHR that reduce the sensitivity of HBV detection assays and could result in false negative, thus 
increasing the risk of ‘‘false’’ OBI58-60.  
 
The prevalence of DFMs, likewise VEMs, has been increasing since massive introduction of the 
vaccine31,32. Therefore, there is growing public concern regarding assay sensitivity to HBsAg mutants 
in clinical diagnosis since selection of DFMs carry implicit risk of false negative results54. In this 
regards, there is a concerted effort to understand how mutants affect “a” determinant 
antigenicity37. 
Fortunately, in recent years, constant development of new enzyme immunoassays with better 
detection limits has improved the sensitivity and specificity of HBsAg assays. Despite this, HBsAg 
assays may vary in their ability to detect HBsAg variants62,63. For this reason, understanding the 
prevalence of HBsAg antigenic variation has become a challenge for diagnostic assays design and 
future changes in the formulation of the vaccine. Consequently, ongoing surveillance of escape 
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The current study found that ARMs were present in 5.1% of cases, with a significantly higher 
prevalence in patients who reported receiving antiviral treatment. 
The prevalence of ARMs observed in the 14 treated patients (78.6%) could be explained as a 
consequence of selection pressure exerted by the antiviral agent and is consistent with previous 
reports29. Treatment selection pressure of ARMs can lead to virological and biochemical 
breakthroughs, hepatitis flares, hepatic decompensation and even death. The most frequent 
mutation (rtM204V/I) was usually accompanied (95% of samples) by a compensatory mutation at 
rtL180M and/or rtV173L, as it has been previously reported29. 
Interestingly, ARMs were observed in 3.1% of the 516 treatment-naïve cases. This may be a 
consequence of either, HBV diversity given by replication through an error-prone polymerase or 
transmission of a mutated variant from patients receiving antiviral therapy to HBV-susceptible 
persons. The finding of ARMs in naïve antiviral therapy patients with HBV infection has important 
epidemiologic and clinical implications. 
Results in this study corroborate previous findings showing prevalences of ARMs that range between 
0 and 5.2%64-69. However, our findings disagree with previous research reporting high rates of 
polymerase mutations70-72. Such variability, as mentioned above, is likely due to differences in the 
study design, uncertainty about prior exposure to antiviral therapy, rate of patients on treatment 
and/or cohort size. Moreover, most of the patients analyzed in the present work were HBV-F and 
none of the previous studies has enrolled such a large number of patients infected with this 
genotype. 
Due to gene overlapping, ARMs induced by antiviral agents, beyond its implication in antiviral 
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Finally, some limitations need to be considered. Firstly, the sequence information to detect VEMs, 
DFMs and ARMs was not determined by next generation sequencing. The Sanger method was used, 
so the presence of minor variants at frequencies <15-20% cannot be excluded. However, there is no 
information about the importance that, not only the presence of mutations but also the mutations 
dominancy (>15-25%), have in the quasispecies infecting a patient on vaccine escape, diagnostic 
failure or treatment outcomes. Secondly, no data about vaccination was collected in this study. 
Nevertheless, taking into account the median age of the analyzed patients (44 years) and that 
vaccination programs in Argentina started in 2000, it is very likely that the great majority of included 
patients were unvaccinated. Lastly, only one single health center in the area of Greater Buenos Aires 
was analyzed. It would be advisable to carry out a broader study including other regions of the 
country to validate the findings at national level. Nevertheless, more than one third of the 
Argentinean population lives in the area of Buenos Aires, so the study can be regarded as an 
acceptable approximation to the current situation73. 
 
In conclusion, the current study provides valuable information about mutants in surface antigen and 
polymerase genes of HBV-infected patients from Argentina. Of particular interest is that HBV-F, the 
most prevalent in South and Central American countries and the most sparsely characterized 
genotype, showed a lower prevalence of VEMs and DFMs but similar prevalence of ARMs when 
compared to HBV-A and HBV-D genotypes. For these reasons, this study constitutes an important 
reference for Latin-American clinicians, who mostly treat patients infected with HBV-F, in order to 
draw up the treatment guidelines and evaluate the efficacy of vaccine and diagnostic assays, in a 
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Table 1. Epidemiological Characteristic of the study population. 
Characteristics Population, N= 530 % 
Age median, years 44 (36-57)  
Gender 
     Male 
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     Positive 
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     Detected 








     Detected 








     Detected 
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Y100C 14 (2.6) 14 (9.4) 13 (43.3) 1 (0.8)         - C <0.001 
Y100W 3 (0.6) 3 (2.0)  3 (2.6)         - NR 0.021 
Q101K 3 (0.6) 3 (2.0)  3 (2.6)         - C 0.021 
Q101P 1 (0.2) 1 (0.7)  1 (0.8)         - NR 0.278 
T118A 3 (0.6)    3 (4.2)  3 (23.1)      C C <0.001 
T118V 9 (1.7)    9 (12.5)  9 (69.2)      C C <0.001 
P120A 1 (0.2)         1 (0.3)  1 (1) C NR 0.699 
P120Q 3 (0.6)         3 (1.0) 2 (0.9) 1 (1) C C 0.340 
T126S 1 (0.2)    1 (1.4)   1 (3.2)     C C 0.041 
A128V 10 (1.9) 1 (0.7)  1 (0.8) 9 (12.5)  9 (69.2)      - C <0.001 
G130N 2 (0.4)    2 (2.8) 1 (5)  1 (3.2)     C C 0.002 
G130R 2 (0.4) 1 (0.7)  1 (0.8) 1 (1.4)    1 (12.5)    NR C 0.176 
▲NT131I 1 (0.2)    1 (1.4)  1 (7.7)      C C 0.041 
M133I 1 (0.2) 1 (0.7)  1 (0.8)         NR C 0.278 
M133L 2 (0.4) 2 (1.3)  2 (1.7)         C NR 0.077 
M133T 4 (0.8) 3 (2.0)  3 (2.5) 1 (1.4)    1 (12.5)    C C 0.053 
†FY134L 2 (0.4) 2 (1.3)  2 (1.7)         C C 0.077 
†FY134N 2 (0.4)    2 (2.8)   1 (3.2) 1 (12.5)    C C 0.002 
P142S 1 (0.2) 1 (0.7)  1 (0.8)         C C 0.278 
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*ST143L 5 (0.9)    5 (6.9)   5 (16.1)     C C <0.001 
D144A 2 (0.4) 1 (0.7)  1 (0.8)      1 (0.3) 1 (0.5)  C C 0.727 
D144E 3 (0.6) 1 (0.7) 1 (3.3)  1 (1.4)  1 (7.7)   1 (0.3) 1 (0.5)  C C 0.544 
D144G 1 (0.2) 1 (0.7)  1 (0.8)         C C 0.278 
G145A 1 (0.2)         1 (0.3)   C C 0.699 
G145R 1 (0.2) 1 (0.7) 1 (3.3)          C C 0.278 
N146S 1 (0.2)         1 (0.3)   - C 0.699 
S154A 1 (0.2) 1 (0.7)           - NR 0.278 
Some positions are polymorphic: 
▲ “N” is the major aa in Genotype A and “T” is the mayor aa in Genotypes D and F. 
† “Y” is the major aa in Genotype D and “F” is the mayor aa in Genotypes A and F. 
* “T” is the major aa in Genotype A and “S” is the mayor aa in Genotypes D and F. 
C: Confirmed, NR: No Reported 
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Table 3. Number of ARM analyzed variants by genotype and subgenotype, N=530. 
Variant Number 
(%) 

























rtL80I 2 (0.4)         2 (0.6) 1 (0.5) 1 (1) ARM 0.699 
rtL80V 2 (0.4)    2 (2.8)  1 (7.7) 1 (3.2)     ARM 0.002 
rtV173L 6 (1.2) 2 (1.3)  2 (1.7) 1 (1.4)  1 (7.7)   3 (0.9) 2 (0.9) 1 (1) ARM 0.917 
rtL180M 20 (3.8) 8 (5.4) 2 (6.7) 6 (5) 1 (1.4)    1 (12.5) 11 (3.6) 7 (3.3) 4 (4.1) ARM 0.331 
rtT184A 1 (0.2) 1 (0.7) 1 (3.3)          ARM 0.278 
rtT184S 3 (0.6) 1 (0.7) 1 (3.3)       2 (0.6) 1 (0.5) 1 (1) ARM 0.788 
rtS202G 3 (0.6)    1 (1.4)   1 (3.2)  2 (0.6)  2 (2) ARM 0.278 
rtS202I 2 (0.4) 1 (0.7)  2 (1.7)         ARM 0.417 
rtM204I 3 (0.6)    2 (2.8)  1 (7.7) 1 (3.2)  1 (0.3)  1 (1) ARM 0.024 
rtM204V 17 (3.2) 6 (4) 1 (3.3) 5 (4.2) 1 (1.4)    1 (12.5) 10 (3.2) 7 (3.3) 3 (3.1) ARM 0.580 
p was calculated for differences between genotypes.  
 
